Kintara Therapeutics

Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients who are failing or resistant to current treatment regimens.

Kintara's second-generation photodynamic therapy (PDT) photosensitizer agent (REM-001) has undergone late stage clinical development in previous clinical trials showing a complete response in approximately 80% of evaluable tumor sites. The lead indication for REM-001 Therapy is unresectable cutaneous metastatic breast cancer (CMBC).

CJC provides consulting services with Greg functioning as (Acting) Head of Operations for the company.

MedaSystems

MedaSystems provides an easy to use, intuitive software solution for Expanded Access management that enables collaboration between life sciences teams and physicians. CJC provides related consultative expertise and services through a non-exclusive partnership with MedaSystems.

CJC provided program management for the RLS-003 drug development program in AKI from manufacturing through completion of a Phase 2 proof-of-concept study and the eventual transfer of the asset.

CJC provided program management support, and website and IT support.

Greg continues to serve on the MedGenesis Board of Directors.

CJC provided several years of support and maintenance for the Vancouver Hospice Society website on a pro bono bases.